Skip to content
‹ Back to IndustriesSciences

With New Research into Hot Flashes During Menopause, Scientists Expand Treatment Options for Women’s Health

Hot flashes during menopause, a common symptom of women’s natural midlife biology, affect more than 80% of women. The causes behind these common hot flashes have remained a mystery to scientists for years. However, recent research has revealed a breakthrough in understanding the root cause of these uncomfortable, sweaty episodes. Researchers from The Queen’s Medical…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · · EstrogenHormone TherapyHot FlashesMenopause
Share

Key takeaways

01

Hot flashes during menopause, a common symptom of women’s natural midlife biology, affect more than 80% of women.

02

The causes behind these common hot flashes have remained a mystery to scientists for years.

03

However, recent research has revealed a breakthrough in understanding the root cause of these uncomfortable, sweaty episodes.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Hot flashes during menopause, a common symptom of women’s natural midlife biology, affect more than 80% of women. The causes behind these common hot flashes have remained a mystery to scientists for years. However, recent research has revealed a breakthrough in understanding the root cause of these uncomfortable, sweaty episodes.

Researchers from The Queen’s Medical Research Institute, the Mayo Clinic’s Center for Translational Science Activities, the Institute for Infectious Diseases and Molecular Medicine at the University of Cape Town, among others, have discovered the root cause of hot flashes is actually non-hormonal. They identified that a particular group of neurons in the brain become activated during menopause, which can cause temperature regulation disturbances leading to hot flashes. The activation of these neurons is due to the decrease of estrogen in the brain’s hypothalamus during menopause.

This discovery is one of many helping scientists better understand the root causes and side effects of menopause. Perhaps the most important consequence of this deeper understanding of hot flashes is that it gives women and their doctors a better framework for understanding the role of hormonal therapy in treating symptoms of menopause.

Much skepticism still surrounds hormone therapy for treating hot flashes during menopause and other menopause symptoms. One 2022 study found links between hormone therapy and increased risks of breast cancer and other health conditions. Other studies showed that the benefits of hormone therapy greatly outweigh the risks. Regardless, the most recent developments around the causes behind hot flashes are providing hope for new, non-hormonal, and perhaps better treatments. One drug, fezolinetant, is a non-hormonal treatment for hot flashes currently under review by the U.S. FDA; the most recent round of clinical trials for the drug found it “reduced the frequency and severity of moderate-to-severe vasomotor symptoms,” otherwise known as hot flashes.

So, can this discovery lead to new non-hormonal targeted therapies for hot flashes during menopause? We sourced perspectives and reactions to this research discovery from menopause and women’s health experts, who seem optimistic about the consequences of these findings.

Barbra’s Thoughts

Barbra Hanna, DO, FACOG, NCMP who is the founder & CEO of MyMenopauseRx has spent the last few years helping women feel well, sleep well and live well with menopause. She is quite excited about the recent discoveries and believes studies like these may lead to non-hormonal treatments to help women lead better lives.

“Estrogens have an important role in every tissue of our body. And hot flashes and night sweats that are debilitating through the menopausal transition really wreak havoc on a woman’s quality of life. Yet, some women can’t or don’t want to use menopausal hormone therapy. The scientific discovery of where those hot flashes and night sweats originate from in our brain is not only fascinating but it’s going to help move science forward to improve the quality of life of so many women.”

Kim’s Thoughts

Can this new research help change society’s attitude and baked-in negative assocations toward menopause? Kim Vopni of Pelvienne Wellness believes it can. Kim is the leading go-to expert for pelvic floor exercise programs that have helped numerous women over the years deal with certain symptoms of menopause. Here are her thoughts on a compendium of reporting out of National Geographic surrounding this and other recent research on menopause.

“I was pleasantly surprised to see an entire section dedicated to vaginal health, specifically genitourinary syndrome of menopause, which is an umbrella term that covers a lot of things that I have been speaking and preaching about for many years and coming up to resistance because the word vagina is considered “inappropriate”, especially in platforms doing to do with social media.

The interesting piece about menopause is actually bringing light. The conversation around menopause is bringing light to pelvic floor disorders. They talked about pelvic floor physical therapy, which in my opinion is the most underused women’s resource that we have. I believe every woman should be seeing one from the time we’re sexually active once a year for the rest of our life, just like we see a dentist once a year for our teeth.

I also like that they did include vaginal, estrogen and the safety surrounding that. I believe and see evidence to support starting it around the time of menopause and staying on it for the rest of our life can help decrease UTIs, can help improve sex, can help with incontinence, all these things that we have thought we need to suffer with.

So, I was really delighted by that particular section. The entire article was well-informed but specific of course to the vaginal piece. I think it was well-informed and I hope that it starts to change the landscape for women going forward.”

Dr. Mindy’s Thoughts

For women in our audience seeking a little advice, how should this new research around menopause help clarify the proper steps and strategies for mitigating menopause’s worst symptoms? Dr. Mindy Pelz, a women’s health and fasting expert, and the founder of Dr. Mindy Pelz Co., reacts to National Geographic’s article and provides perspectives on menopause symptom treatment.

“I wanna highlight a couple of important parts of this article. One, everything the article talks about, the hormonal changes that are happening, are really real for women. The hot flashes, the weight gain, the trouble sleeping. Everything starts to shift after 40, and so your lifestyle needs to shift with those hormones. Things like making sure that you are intermittent fasting and adding in some…cycling in the ketogenic diet and looking at your toxic load. Those all become massively important as you go through the menopausal years.

Now the other thing that this article brings up is that we’re revisiting HRT, and I think this is a great thing. We should look at HRT, we should look at bioidenticals, and look at where the safety is for those specific medications for menopausal women. But we can’t look at medication as the only solution. We’re gonna have to pair a healthy lifestyle to it.

So the article really brought to the surface some important topics that aren’t being discussed culturally. So thank you, National Geographic, but I also wanna highlight that we do need to dive into lifestyle. What are the lifestyle changes and what’s the appropriate medication for you? There is not a one size fits all to these symptoms, and so understanding yourself and what’s gonna working with your doctor to figure out what’s best for you becomes imperative.”

Article written by Galina Mikova.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512